Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Agonists

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    356 result(s) found for: Agonists. Displaying page 18 of 18.
    «« First « Previous 10  11  12  13  14  15  16  17  18 
    EudraCT Number: 2018-002990-24 Sponsor Protocol Number: RAD1901-308 Start Date*: 2019-05-29
    Sponsor Name:Stemline Therapeutics, Inc.
    Full Title: Elacestrant Monotherapy vs. Standard of Care for the Treatment of Patients with ER+/HER2- Advanced Breast Cancer Following CDK4/6 Inhibitor Therapy: A Phase 3 Randomized, Open-Label, Active-Control...
    Medical condition: Advanced breast cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10072737 Advanced breast cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) FR (Ongoing) HU (Completed) AT (Completed) GR (Completed) IE (Completed) PT (Completed) DK (Completed) ES (Ongoing) GB (GB - no longer in EU/EEA) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-004610-95 Sponsor Protocol Number: 228PD201 Start Date*: 2018-05-01
    Sponsor Name:Biogen Idec Research Limited
    Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study, with an Active-Treatment Dose-Blinded Period, to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of BIIB054 ...
    Medical condition: Parkinson's Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10061536 Parkinson's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) AT (Completed) DE (Completed) FR (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2018-001616-30 Sponsor Protocol Number: CORT125134-452 Start Date*: 2018-07-09
    Sponsor Name:Corcept Therapeutics Incorporated
    Full Title: An Open-Label Extension Study of the Safety of Relacorilant (CORT125134) in the Treatment of the Signs and Symptoms of Endogenous Cushing Syndrome
    Medical condition: Endogenous Cushing Syndrome
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004860 10011657 Cushings syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) ES (Ongoing) BG (Trial now transitioned) DE (Trial now transitioned) IT (Trial now transitioned) NL (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-001072-37 Sponsor Protocol Number: IRFMN-EN-7556 Start Date*: 2019-01-29
    Sponsor Name:IRCCS - Istituto di Ricerche Farmacologiche Mario Negri
    Full Title: AtTEnd: Atezolizumab Trial in Endometrial cancer - Phase III double-blind randomized placebo controlled trial of atezolizumab in combination with paclitaxel and carboplatin in women with advanced/r...
    Medical condition: Newly diagnosed, histologically-confirmed stage III-IV endometrial carcinoma/carcinosarcoma with residual disease after surgery, either measurable or evaluable, and naïve to first line systemic ant...
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10014772 Endometrioid adenocarcinoma recurrent LLT
    21.1 100000004864 10014776 Endometrioid adenocarcinoma stage III LLT
    21.1 100000004864 10014777 Endometrioid adenocarcinoma stage IV LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (GB - no longer in EU/EEA) AT (Completed) ES (Ongoing) DE (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-003732-30 Sponsor Protocol Number: NbT 01-06 / TULEP 1 Start Date*: 2007-01-31
    Sponsor Name:Axxonis Pharma AG
    Full Title: Transdermal Use of Lisuride in Early Parkinson´s Disease: A double blind, randomized, Placebo and Pramipexole controlled study to evaluate the efficacy and safety of Lisuride TTS
    Medical condition: Early Parkinson's Disease
    Disease: Version SOC Term Classification Code Term Level
    8.1 10061536 Parkinson's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing) PL (Ongoing) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-003187-44 Sponsor Protocol Number: UC-0140/1208 Start Date*: 2012-09-25
    Sponsor Name:UNICANCER
    Full Title: Randomized, double-blind, multicentric phase III trial evaluating the safety and benefit of adding everolimus to adjuvant hormone therapy in women with poor prognosis, ER+ and HER2- primary breast ...
    Medical condition: women with poor prognosis, ER+ and HER2- primary breast cancer who remain free of disease after receiving 3 years of adjuvant hormone therapy
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FR (Trial now transitioned) BE (Trial now transitioned) GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2009-015161-31 Sponsor Protocol Number: P04938 Start Date*: 2010-08-17
    Sponsor Name:Schering-Plough Research Institute, a division of Schering Corporation
    Full Title: A Phase 3, 12-Week, Double-Blind, Double-Dummy, Placebo- and Active-Controlled Efficacy and Safety Study of Preladenant in Subjects With Moderate to Severe Parkinson’s Disease (Phase 3; Protocol No...
    Medical condition: Parkinson's disease
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10061536 Parkinson's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) GB (Completed) CZ (Completed) FR (Completed) NL (Completed) ES (Completed) AT (Completed) DE (Completed) IT (Completed) SE (Completed) PT (Completed) BG (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2013-002133-37 Sponsor Protocol Number: COR-2012-01 Start Date*: 2014-11-17
    Sponsor Name:Cortendo AB
    Full Title: An Open Label Study to Assess the Safety and Efficacy of COR—003 (2S, 4R-Ketoconazole) in the Treatment of Endogenous Cushing’s Syndrome
    Medical condition: Endogenous Cushing's syndrome (CS) or Cushing's disease
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004860 10011657 Cushings syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) ES (Completed) BE (Completed) NL (Completed) SE (Completed) DK (Completed) DE (Completed) IT (Completed) BG (Completed) CZ (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2010-024614-66 Sponsor Protocol Number: C38072/3082 Start Date*: 2011-07-20
    Sponsor Name:Teva Branded Pharmaceutical Products R&D, Inc
    Full Title: A 12-Month, Double-Blind, Placebo-Controlled, Parallel-Group Study to evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the reduction of Clinical Asthma Exacerbations in Patients (12-75...
    Medical condition: Treatment for patients with eosinophilic asthma
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004855 10068462 Eosinophilic asthma LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) SE (Completed) CZ (Completed) DK (Completed) HU (Completed) PL (Completed)
    Trial results: Removed from public view
    EudraCT Number: 2008-007969-23 Sponsor Protocol Number: CC-5013-PC-002 Start Date*: 2010-04-09
    Sponsor Name:Celgene Corporation
    Full Title: A PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF DOCETAXEL AND PREDNISONE WITH OR WITHOUT LENALIDOMIDE IN SUBJECTS WITH CASTRATE-RESISTANT PROSTATE CANCER
    Medical condition: Chemo-naïve metastatic prostate cancer subjects with documented rising Prostate Specific Antigen (PSA) or documented Progressive Disease (PD) following hormonal therapy
    Disease: Version SOC Term Classification Code Term Level
    16.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: BE (Completed) HU (Completed) CZ (Prematurely Ended) DE (Completed) GB (Completed) AT (Completed) NL (Completed) IT (Completed) ES (Completed) DK (Completed) SE (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2018-004887-74 Sponsor Protocol Number: AC-065D301 Start Date*: 2019-08-14
    Sponsor Name:Actelion Pharmaceuticals Ltd
    Full Title: A Multicenter, Randomized, Double-blind, Placebo-controlled Study in Participants with Sarcoidosis-associated Pulmonary Hypertension (SAPH) to Assess the Efficacy and Safety of Oral Selexipag.
    Medical condition: sarcoidosis-associated pulmonary hypertension (SAPH)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10037400 Pulmonary hypertension PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) NL (Completed) DE (Completed) HU (Prematurely Ended) PL (Completed) ES (Ongoing) BE (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-000091-28 Sponsor Protocol Number: EFC15081 Start Date*: 2017-09-04
    Sponsor Name:Sanofi-aventis recherche & développement
    Full Title: Six-month, Randomized, Open-label, Parallel-group Comparison of SAR341402 to NovoLog®/NovoRapid® in Adult Patients With Diabetes Mellitus Also Using Insulin Glargine, with a 6-month Safety Extensio...
    Medical condition: Type 1 diabetes mellitus Type 2 diabetes mellitus
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    20.0 10027433 - Metabolism and nutrition disorders 10067584 Type 1 diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) FI (Completed) DE (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2020-000209-10 Sponsor Protocol Number: D8731C00002 Start Date*: 2020-10-20
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase II, Open-label Study to Assess the Efficacy, Safety, and Tolerability of AZD4635 in Combination with Durvalumab and in Combination with Cabazitaxel and Durvalumab in Patients Who Have Progr...
    Medical condition: Progressive Metastatic Castrate-Resistant Prostate Cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: BE (Completed) DE (Completed) FR (Completed) DK (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2007-000074-23 Sponsor Protocol Number: 248.525 Start Date*: 2007-05-11
    Sponsor Name:Boehringer Ingelheim Limited
    Full Title: A double-blind, double-dummy, placebo-controlled, randomized, three parallel groups study comparing the Efficacy, Safety and Tolerability of Pramipexole ER versus placebo and versus Pramipexole IR ...
    Medical condition: Male or female patients, with idiopathic PD diagnosed for at least 2 years, 30 years of age or older at time of diagnosis, with a modified Hoehn and Yahr scale of 2 to 4 at on-time.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10061536 Parkinson's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) SE (Completed) IT (Completed) CZ (Completed) HU (Completed) AT (Completed) SK (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2016-003162-13 Sponsor Protocol Number: CO-338-052 Start Date*: 2017-02-10
    Sponsor Name:Clovis Oncology, Inc.
    Full Title: TRITON2: A Multicenter, Open-label Phase 2 Study of Rucaparib in Patients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency
    Medical condition: Metastatic castration-resistant prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10076506 Castration-resistant prostate cancer LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (GB - no longer in EU/EEA) IE (Completed) ES (Completed) BE (Completed) DK (Completed) FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2010-022064-12 Sponsor Protocol Number: EFC11784 Start Date*: 2011-03-23
    Sponsor Name:sanofi-aventis R&D
    Full Title: Randomized, Open Label, Multi-Center Study comparing Cabazitaxel at 25 mg/m2 and at 20 mg/m² in Combination with Prednisone Every 3 Weeks to Docetaxel in Combination with Prednisone in Patients wit...
    Medical condition: metastatic Castration Resistant Prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060862 Prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: SE (Completed) CZ (Completed) ES (Completed) FI (Completed) DK (Completed) PT (Completed) IT (Completed) DE (Completed) RO (Completed) PL (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 10  11  12  13  14  15  16  17  18 
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun Jun 01 00:47:02 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA